Read MorePharma M&A is back – can it cure the sector's ills?
"It's important in our industry to become more efficient. We have tremendous pressures on all our companies."
On Thursday, AstraZeneca reported a rise in revenues but declining profits for the first quarter, as the debate over its future continued.
Revenues rose by 3 percent from the same time in 2013 to $6.4 billion, but core operating profit for the quarter was down 11 percent to $1.95 billion.
Earnings per share fell by 40 percent to $0.40 for the quarter, following the high-profile disposal of its former flagship research center near Manchester. The company's share price fell slightly in early London trading.
The company has recently become the focus of takeover speculation after it emerged that Pfizer, the biggest company in the sector, made a preliminary approach in late 2013. AstraZeneca has declined to comment on the approach.
Read MorePfizer takeover of AstraZeneca isn't as crazy as it sounds
One of its biggest attractions for an acquirer is its pipeline of new cancer drugs. AstraZeneca has recently brought forward several of these to the final stages of clinical trials.